Maricann Group Inc. Secures Second-Site Sales Licence in Canada
TORONTO, Ontario, September 5, 2017 – Maricann Group Inc. (CSE:MARI) (“Maricann” or the “Company”) announced today that it has secured a second-site sales licence for its location in Burlington, ON Canada through its wholly owned subsidiary Maricann Inc. The sales licence is the second granted to Maricann by Health Canada, with the first applying to the company’s cultivation and processing facility in Langton, ON. With the granting of the new licence, Maricann is shifting its client services, sales operations and research activities to Burlington.
The establishment of the Burlington site helps Maricann centralize and streamline numerous sales and marketing processes, including potential same day delivery within the Greater Toronto Area, and next day delivery across Canada. Maricann is now moving through the process of establishing its analytical laboratory functions at the Burlington site, to assist in medical research efforts. This is expected to help scale the business at a faster rate.
“The new headquarters in Burlington will centralize our sales, marketing and customer services operations under one roof, which will ultimately create greater efficiencies throughout the company. Importantly, In the near future, we expect to conduct analytical testing and bench research onsite. Overall, the move sets up Maricann for much greater future growth.” said Benjamin Ward, CEO of Maricann.
Maricann will soon be rolling out new service offerings to clients, such as customer service live chat on its website. As part of Maricann’s commitment to maintaining a low carbon footprint, client services will now transition to a 100% paperless system, while still complying with all Health Canada requirements.
About Maricann Group Inc.
Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Toronto, Canada and Munich, Germany, with production facilities in Langton, Ontario, Canada where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada and Dresden, Germany. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a fully funded 517,000 sq. ft. (48,030 sq. m) build out, that when complete will supply 57,245 kg of increased cannabis dry flower production capacity to support existing and future patient growth.
For more information about Maricann, please visit our website at www.maricann.ca
Forward Looking Information
Certain statements in this document contain forward-looking statements which can be identified by the use of forward-looking terminology such as “believes”, “expects”, “may”, “desires”, “will”, “should”, “projects”, “estimates”, “contemplates”, “anticipates”, “intends”, or any negative such as “does not believe” or other variations thereof or comparable terminology. No assurance can be given that potential future results or circumstances described in the forward-looking statements will be achieved or will occur. By their nature, these forward-looking statements, necessarily involve risks and uncertainties, including those discussed herein, that could cause actual results to significantly differ from those contemplated by these forward-looking statements. Such statements reflect the view of the Company with respect to future events, and are based on information currently available to the Company and on assumptions, which it considers reasonable. Management cautions readers that the assumptions relative to the future events, several of which are beyond Management’s control, could prove to be incorrect, given that they are subject to certain risk and uncertainties, and that actual results may differ materially from those projected. Factors which could cause results or events to differ from current expectations include, among other things: fluctuations in operating results; the impact of general economic, industry and market conditions; the ability to recruit and retain qualified employees; fluctuations in cash flow; increased levels of outstanding debt and obligations under a capital lease; expectations regarding market demand for particular products and the dependence on new product development; the impact of market change; and the impact of price and product competition. Management disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking information.
VP Investor Relations
North 6th Agency
Corporate Headquarters (Canada)
Maricann Group Inc. (Toronto)
845 Harrington Court, Unit 3
Burlington Ontario L7N 3P3
European Headquarters (Germany)
Thierschstrasse 3, 80538 Munchen, Deutschland
The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.